Po‐Ting Lin

Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first‐line treatment for unresectable hepatocellular carcinoma

Chung‐Wei Su, Wei Teng, Po‐Ting Lin et al. · Cancer Medicine · 2022 · 33 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +13

Concurrent Atezolizumab Plus Bevacizumab and High-Dose External Beam Radiotherapy for Highly Advanced Hepatocellular Carcinoma

Chung‐Wei Su, Wei Teng, Eric Yi-Liang Shen et al. · The Oncologist · 2024 · 30 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Combining immune checkpoint inhibitor with lenvatinib prolongs survival than lenvatinib alone in sorafenib-experienced hepatocellular carcinoma patients

Po‐Ting Lin, Wei Teng, Wen‐Juei Jeng et al. · European Journal of Gastroenterology & Hepatology · 2020 · 18 citations

Medicine, Oncology, Pharmacotherapy +17

Clinical and Dosimetric Results of Proton or Photon Radiation Therapy for Large (>5 cm) Hepatocellular Carcinoma: A Retrospective Analysis

Cheng‐En Hsieh, Ching‐Hsin Lee, Hsiao‐Chieh Huang et al. · International Journal of Radiation Oncology*Biology*Physics · 2023 · 18 citations

Medicine, Oncology, Radiation Oncology +17

Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma– with Emphasis on Locoregional Therapy for Oligoprogression

Tsung‐Hao Liu, San‐Chi Chen, Kun‐Ming Rau et al. · Liver Cancer · 2024 · 17 citations · Full text

Medicine, Immunology, Oncology +17